Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Cancer

Volumn 121, Issue 18, 2015, Pages 3212-3220

  Naidoo, Jarushka ^a   Sima, Camelia S ^a   Rodriguez, Katherine ^a   Busby, Natalie ^a   Nafa, Khedoudja ^a   Ladanyi, Marc ^a   Riely, Gregory J ^a,b   Kris, Mark G ^a,b   Arcila, Maria E ^a   Yu, Helena A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

advanced; epidermal growth factor receptor (EGFR); erlotinib; exon 20 insertion; lung adenocarcinoma

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PEMETREXED; PLATINUM COMPLEX; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; AGED; ARTICLE; BASE PAIRING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; ETHNICITY; EXON; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG ADENOCARCINOMA; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; ADENOCARCINOMA; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROTO ONCOGENE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; EXONS; FEMALE; GENES, ERBB-1; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84940961649     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29493     Document Type: Article

References (37)

1. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
2. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
3. Pao W, Miller V, Zakowski M, et al., EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311.
4. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
5. Han JY, Park K, Kim SW, et al., First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30: 1122-1128.
6. Mitsudomi T, Morita S, Yatabe Y, et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
7. Maemondo M, Inoue A, Kobayashi K, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
8. Zhou C, Wu YL, Chen G, et al., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-742.
9. Rosell R, Carcereny E, Gervais R, et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
10. Sequist LV, Yang JC, Yamamoto N, et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3327-3334.
11. Kris MG, Johnson BE, Berry LD, et al., Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311: 1998-2006.
12. Beau-Faller M, Prim N, Ruppert AM, et al., Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014; 25: 126-131.
13. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T,. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004; 64: 8919-8923.
14. Pan Q, Pao W, Ladanyi M,. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005; 7: 396-403.
15. Arrieta O, Cardona AF, Corrales L, et al., The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer. 2015; 87: 169-175.
16. Yang JC, Shih JY, Su WC, et al., Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012; 13: 539-548.
17. Yasuda H, Park E, Yun CH, et al., Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013; 5: 216ra177.
18. Arcila ME, Nafa K, Chaft JE, et al., EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013; 12: 220-229.
19. Oxnard GR, Lo PC, Nishino M, et al., Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013; 8: 179-184.
20. Sasaki H, Endo K, Takada M, et al., EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer. 2007; 58: 324-328.
21. Wu JY, Wu SG, Yang CH, et al., Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008; 14: 4877-4882.
22. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland A, Brustugun OT,. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol. 2012; 7: 1471-1473.
23. Rekhtman N, Paik PK, Arcila ME, et al., Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012; 18: 1167-1176.
24. Su Z, Dias-Santagata D, Duke M, et al., A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011; 13: 74-84.
25. Scagliotti GV, Parikh P, von Pawel J, et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
26. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W,. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011; 17: 5530-5537.
27. Costa DB, Halmos B, Kumar A, et al., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007; 4: 1669-1679.
28. Yu HA, Arcila ME, Rekhtman N, et al., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19: 2240-2247.
29. Lammers PE, Lovly CM, Horn L,. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw. 2014; 12: 6-11.
30. Ludovini V, Bianconi F, Pistola L, et al., Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6: 707-715.
31. Ji H, Ramsey MR, Hayes DN, et al., LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007; 448: 807-810.
32. Matsumoto S, Iwakawa R, Takahashi K, et al., Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007; 26: 5911-5918.
33. Huang CL, Taki T, Adachi M, et al., Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol. 1998; 12: 553-563.
34. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K,. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer. 1997; 75: 1125-1130.
35. Koivunen JP, Kim J, Lee J, et al., Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer. 2008; 99: 245-252.
36. Chen Z, Cheng K, Walton Z, et al., A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012; 483: 613-617.
37. Carretero J, Shimamura T, Rikova K, et al., Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 2010; 17: 547-559.